Skip to content

Our Global Partners

Using Heart together, because every heartbeat matters

World Heart Day is proud to partner with AstraZeneca, Boehringer Ingelheim and Lilly alliance, and Pfizer.

Our global partners help us tirelessly in our movement to reduce cardiovascular disease (CVD) around the world.

This World Heart Day, we’ve joined forces to make World Heart Day more powerful than ever. With their support, we are raising awareness and encouraging individuals, families, communities and governments to drive the CVD agenda and help people live longer, better, more heart-healthy lives.

Thank you to AstraZeneca, Boehringer Ingelheim and Lilly alliance, and Pfizer, our official global partners for World Heart Day, for their collaboration.

AstraZeneca’s aim is to protect the lives of millions of people across the world from the often-devastating consequences of cardiovascular, renal and metabolic diseases.

AstraZeneca and the World Heart Federation will work in close collaboration to drive global action to prevent, control, and reduce the burden of cardiovascular disease and its associated risks and complications. Such synergy will tackle key issues in cardiovascular care through international policy, advocacy and disease awareness initiatives, and by supporting global and local activations to assist those at particularly high risk.

Our partnership will be founded on the shared ambition to help individuals living with cardiovascular, metabolic and renal diseases receive adequate standards of care and manage their condition so as to live longer, healthier lives.

The Boehringer Ingelheim and Lilly Alliance are driven to transform care for people with cardio-renal-metabolic conditions, a group of interconnected disorders that affect more than one billion people worldwide and are a leading cause of death.

The cardiovascular, renal and metabolic systems are interconnected, and share many of the same risk factors and pathological pathways along the disease continuum. Dysfunction in one system may accelerate the onset of others, resulting in progression of interconnected diseases such as type 2 diabetes, cardiovascular disease, heart failure, and kidney disease, which in turn leads to an increased risk of cardiovascular death. Conversely, improving the health of one system can lead to positive effects throughout the others.

This World Heart Day, we are proud to continue to support the World Heart Federation. Through our research and treatments, our goal is to support people’s health, restoring the balance between the interconnected cardio-renal-metabolic systems and reducing their risk of serious complications. As part of our commitment to those whose health is jeopardized by cardio-renal-metabolic conditions, we will continue embracing a multidisciplinary approach towards care and focusing our resources on filling treatment gaps.

This World Heart Day, we are proud to partner with the World Heart Federation to support their mission to achieve heart health equity for all.

At Pfizer, we are united by a single purpose – to deliver breakthroughs that change patients’ lives. Every day, Pfizer colleagues from around the world work to address areas of significant unmet medical need. Nowhere is this need greater than in rare disease.

There are more than 7,000 known rare diseases. One of these is called transthyretin amyloid cardiomyopathy or ATTR-CM, which is a form of cardiac amyloidosis. ATTR-CM is a rare, underdiagnosed, and fatal condition, resulting in progressive heart failure.

This year, we continue our partnership with the World Heart Federation to support the cardiology community and share how we at Pfizer, ‘use heart.’ We ‘use heart’ to pioneer innovation. We ‘use heart’ to champion health equity. We ‘use heart’ to improve care for all those living with cardiovascular disease, including those living with rare conditions, such as ATTR-CM. This year, we hope to inspire others to share how they ‘use heart’ to support the cardiac amyloidosis community.